BioLineRx Ltd.
BLRX
$2.75
-$0.32-10.42%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 194.00K | 427.00K | 304.00K | 255.00K | 11.75M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 194.00K | 427.00K | 304.00K | 255.00K | 11.75M |
| Cost of Revenue | 40.00K | 84.00K | 72.00K | 34.00K | 6.09M |
| Gross Profit | 154.00K | 343.00K | 232.00K | 221.00K | 5.66M |
| SG&A Expenses | 1.12M | 831.00K | 209.00K | 989.00K | 6.97M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 3.58M | 2.63M | 2.61M | 2.65M | 14.92M |
| Operating Income | -3.39M | -2.21M | -2.30M | -2.39M | -3.17M |
| Income Before Tax | -2.24M | -977.00K | -3.94M | 5.13M | -3.19M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -2.24M | -977.00K | -3.94M | 5.13M | -3.19M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | 851.00K | -- | -- | -- | -- |
| Net Income | -1.39M | -977.00K | -3.94M | 5.13M | -3.19M |
| EBIT | -3.39M | -2.21M | -2.30M | -2.39M | -3.17M |
| EBITDA | -3.33M | -2.09M | -2.13M | -2.23M | -1.39M |
| EPS Basic | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Normalized Basic EPS | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| EPS Diluted | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Normalized Diluted EPS | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Average Basic Shares Outstanding | 2.66B | 2.61B | 2.37B | 2.22B | 1.31B |
| Average Diluted Shares Outstanding | 2.66B | 2.61B | 2.37B | 2.22B | 1.31B |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |